Sign in
CompletedPhase 4

Comparative Study of Leflunomide Plus Methotrexate Versus Methotrexate Monotherapy in Refractory Polyarticular Juvenile Idiopathic Arthritis Patients

Key facts

Who runs it
Bangladesh Medical University
Where
Bangladesh1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 4
People taking part
50 people enrolled
Started
1 Mar 2024
Ended
28 Jan 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Leflunomide plus Methotrexate
  • Methotrexate Monotherapy
Record updated
23 February 2026

Who can take part

Age
1 day to 15 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • All diagnosed cases of Refractory Polyarticular Juvenile Idiopathic Arthritis (JIA) according to ILAR, 2001 unresponsive to methotrexate (at standard dose of 15mg/m² body surface area at least 3-6 months) as monotherapy or together with low dose steroid as bridge therapy who attended Paediatric Rheumatology Division (OPD clinic and inpatient), Department of Paediatrics of BMU, during the study period

Who cannot take part

  • 1. A patient with prior or current infectious disorders, including active/latent tuberculosis, and/or H/O chronic or recurrent severe infections, including opportunistic infections; A patient with leucopenia (White blood cell count < 3000/mm3), neutropenia (Neutrophil count < 1000/mm3) and thrombocytopenia (Platelet count < 100000/mm3); Serum creatinine > upper limit of normal reference range. 4. Alanine aminotransaminase (ALT) more than 2 times of upper normal limit. 5. All diagnosed cases of refractory polyarticular JIA who did not give the consent during the study period

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

A randomized control trial open level and parallel design was conducted in the department of paediatrics, Bangladesh Medical University (BMU). All diagnosed cases of Refractory Polyarticular JIA according to ILAR criteria, unresponsive to MTX were enrolled in this study. After getting written informed consent from the parents/legal guardians, a detailed structured data collection sheet was used for data collection. After enrollment all participants were allocated into experimental group and control group by randomization using random allocation software version 2.0. Total sample size of this study is 50 and 25 participants in each group. All patients of experimental group were given leflunomide along with existing MTX in refractory polyarticular JIA patients and injectable MTX were given at standard dose(15mg/m² BSA) Considering high disease activity steroid were continued in both group at low bridging dose 0.05-1 mg/kg/dose. Patient's disease activity status was assessed by JADAS-27 at initial visit, 6th weeks, 12 weeks and 24 weeks. Functional impairment was assessed by CHAQ-B (DI) at baseline and 24th weeks of treatment. Statistical analysis of the collected data were carried out by using an appropriate statistical tool.

The 2 groups in the trial

  • Leflunomide plus Methotrexate (Experimental group)Treatment being tested

    Experimental group

    Treatment: Leflunomide plus Methotrexate

  • Methotrexate Monotherapy (Control Group)Existing treatment, for comparison

    Control group

    Treatment: Methotrexate Monotherapy

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
23 February 2026